Fatty acid-induced insulin resistance: role of insulin receptor substrate 1 serine phosphorylation in the retroregulation of insulin signalling

Insulin resistance, when combined with impaired insulin secretion, contributes to the development of type 2 diabetes. Insulin resistance is characterized by a decrease in the insulin effect on glucose transport in muscle and adipose tissue. Tyrosine phosphorylation of IRS-1 (insulin receptor substra...

Full description

Saved in:
Bibliographic Details
Published in:Biochemical Society transactions Vol. 31; no. Pt 6; p. 1152
Main Authors: Le Marchand-Brustel, Y, Gual, P, Grémeaux, T, Gonzalez, T, Barrès, R, Tanti, J-F
Format: Journal Article
Language:English
Published: England 01-12-2003
Subjects:
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract Insulin resistance, when combined with impaired insulin secretion, contributes to the development of type 2 diabetes. Insulin resistance is characterized by a decrease in the insulin effect on glucose transport in muscle and adipose tissue. Tyrosine phosphorylation of IRS-1 (insulin receptor substrate 1) and its binding to PI 3-kinase (phosphoinositide 3-kinase) are critical events in the insulin signalling cascade leading to insulin-stimulated glucose transport. Various studies have implicated lipids as a cause of insulin resistance in muscle. Elevated plasma fatty acid concentrations are associated with reduced insulin-stimulated glucose transport activity as a consequence of altered insulin signalling through PI 3-kinase. Modification of IRS-1 by serine phosphorylation could be one of the mechanisms leading to a decrease in IRS-1 tyrosine phosphorylation, PI 3-kinase activity and glucose transport. Recent findings demonstrate that non-esterified fatty acids, as well as other factors such as tumour necrosis factor alpha, hyperinsulinaemia and cellular stress, increase the serine phosphorylation of IRS-1 and identified Ser(307) as one of the phosphorylated sites. Moreover, several kinases able to phosphorylate this serine residue have been identified. These exciting results suggest that Ser(307) phosphorylation is a possible hallmark of insulin resistance in biologically insulin-responsive cells or tissues. Identification of IRS-1 kinases could enable rational drug design in order to selectively inhibit the activity of the relevant enzymes and generate a novel class of therapeutic agents for type 2 diabetes.
AbstractList Insulin resistance, when combined with impaired insulin secretion, contributes to the development of type 2 diabetes. Insulin resistance is characterized by a decrease in the insulin effect on glucose transport in muscle and adipose tissue. Tyrosine phosphorylation of IRS-1 (insulin receptor substrate 1) and its binding to PI 3-kinase (phosphoinositide 3-kinase) are critical events in the insulin signalling cascade leading to insulin-stimulated glucose transport. Various studies have implicated lipids as a cause of insulin resistance in muscle. Elevated plasma fatty acid concentrations are associated with reduced insulin-stimulated glucose transport activity as a consequence of altered insulin signalling through PI 3-kinase. Modification of IRS-1 by serine phosphorylation could be one of the mechanisms leading to a decrease in IRS-1 tyrosine phosphorylation, PI 3-kinase activity and glucose transport. Recent findings demonstrate that non-esterified fatty acids, as well as other factors such as tumour necrosis factor alpha, hyperinsulinaemia and cellular stress, increase the serine phosphorylation of IRS-1 and identified Ser(307) as one of the phosphorylated sites. Moreover, several kinases able to phosphorylate this serine residue have been identified. These exciting results suggest that Ser(307) phosphorylation is a possible hallmark of insulin resistance in biologically insulin-responsive cells or tissues. Identification of IRS-1 kinases could enable rational drug design in order to selectively inhibit the activity of the relevant enzymes and generate a novel class of therapeutic agents for type 2 diabetes.
Author Gual, P
Tanti, J-F
Barrès, R
Le Marchand-Brustel, Y
Grémeaux, T
Gonzalez, T
Author_xml – sequence: 1
  givenname: Y
  surname: Le Marchand-Brustel
  fullname: Le Marchand-Brustel, Y
  email: lemarcha@unice.fr
  organization: INSERM Unité U 568, Faculty of Medicine, Avenue de Valombrose, 06107 Nice Cedex 02, France. lemarcha@unice.fr
– sequence: 2
  givenname: P
  surname: Gual
  fullname: Gual, P
– sequence: 3
  givenname: T
  surname: Grémeaux
  fullname: Grémeaux, T
– sequence: 4
  givenname: T
  surname: Gonzalez
  fullname: Gonzalez, T
– sequence: 5
  givenname: R
  surname: Barrès
  fullname: Barrès, R
– sequence: 6
  givenname: J-F
  surname: Tanti
  fullname: Tanti, J-F
BackLink https://www.ncbi.nlm.nih.gov/pubmed/14641015$$D View this record in MEDLINE/PubMed
BookMark eNpNUMtOwzAQ9KGIPuDCByD_QMBrO0nNDVUUkCpxgXPlxOvWKLUj2znkK_hlIlGkHnZnNKuZkXZJZj54JOQO2AMwyR-blJkAgJLPyIIJxooSeD0ny5S-GQMJsrom82lLYFAuyM9W5zxS3TpTOG-GFg11Pg2d8zRicilr3-ITjaFDGuzFrcU-h0jTMFVGnZECTRidR9ofQ5omjp3OLvjJQ_MRJ0uOIeJhOMsXackdvO4mdrghV1Z3CW_PuCJf25fPzVux-3h93zzvilZAnQuxXtcVR1NzY4WUQohalQqbtZSNYkoYa6XhttJSKYsVthxqVYExXGhVWctX5P4vtx-aE5p9H91Jx3H__xn-C9LaaK4
CitedBy_id crossref_primary_10_2515_therapie_2007052
crossref_primary_10_3390_ijms21144900
crossref_primary_10_1007_s00394_018_1730_1
crossref_primary_10_1007_s40708_016_0036_4
crossref_primary_10_1038_nature02866
crossref_primary_10_1210_en_2011_1881
crossref_primary_10_1016_j_bbrc_2007_08_004
crossref_primary_10_1210_jc_2009_1293
crossref_primary_10_3389_fimmu_2024_1370658
crossref_primary_10_1017_S1751731119003215
crossref_primary_10_1042_CS20080253
crossref_primary_10_1021_jf5024092
crossref_primary_10_1016_j_plipres_2010_05_003
crossref_primary_10_1016_j_cbi_2014_05_011
crossref_primary_10_1079_PNS2005445
crossref_primary_10_2337_db08_1077
crossref_primary_10_1016_j_bmcl_2015_11_099
crossref_primary_10_3390_antiox13040485
crossref_primary_10_1139_h06_101
crossref_primary_10_1007_s11010_006_2492_2
crossref_primary_10_3389_fendo_2022_816229
crossref_primary_10_1079_PNS2004405
crossref_primary_10_2337_db06_0384
crossref_primary_10_1016_j_diabet_2008_04_002
crossref_primary_10_1074_jbc_M505531200
crossref_primary_10_1074_jbc_M702472200
crossref_primary_10_1016_j_cellsig_2011_05_004
crossref_primary_10_1016_j_domaniend_2006_06_002
crossref_primary_10_1016_j_diabres_2006_10_010
crossref_primary_10_1007_s00281_013_0407_3
crossref_primary_10_1002_dmrr_636
crossref_primary_10_1021_acs_analchem_7b03191
crossref_primary_10_3390_nu10111623
crossref_primary_10_1080_19768354_2016_1207703
crossref_primary_10_1042_BST0320999
crossref_primary_10_1016_j_taap_2013_09_004
crossref_primary_10_1007_s10534_005_3707_9
crossref_primary_10_3168_jds_2015_10547
crossref_primary_10_1136_bmjdrc_2020_001468
crossref_primary_10_1080_13813455_2018_1448422
crossref_primary_10_1016_j_cvfa_2013_04_002
crossref_primary_10_3390_biology11030382
crossref_primary_10_3390_cells11010167
crossref_primary_10_1210_jc_2008_1400
crossref_primary_10_1007_s00424_015_1721_5
crossref_primary_10_3168_jds_2015_9341
crossref_primary_10_2337_db06_0840
crossref_primary_10_1079_NRR2006120
crossref_primary_10_3168_jds_2023_23904
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1042/bst0311152
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
Biology
ExternalDocumentID 14641015
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GroupedDBID ---
-DZ
-~X
.55
.GJ
0R~
23N
2WC
3O-
4.4
53G
5GY
5RE
6J9
A8Z
AABGO
AAHRG
AAKDD
ABEFU
ABJNI
ABTAH
ACGFO
ACGFS
ACNCT
AEGXH
AENEX
AFFNX
AFHIN
AI.
AIAGR
ALMA_UNASSIGNED_HOLDINGS
C1A
CGR
CS3
CUY
CVF
DU5
E3Z
EBD
EBS
ECM
EIF
EJD
EMOBN
ESTFP
F20
F5P
GX1
H13
HZ~
IH2
ML-
MV1
MVM
NPM
NTEUP
O9-
OHT
P2P
RHI
RNS
RPO
SV3
TWZ
UBE
VH1
X7M
XOL
ZGI
ZXP
ZY4
~02
~KM
ID FETCH-LOGICAL-c317t-388762ed72df3443337959eb844b9093dff4d2f6a499fe6ec217961dd23a96ff2
ISSN 0300-5127
IngestDate Sat Sep 28 08:38:06 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue Pt 6
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c317t-388762ed72df3443337959eb844b9093dff4d2f6a499fe6ec217961dd23a96ff2
PMID 14641015
ParticipantIDs pubmed_primary_14641015
PublicationCentury 2000
PublicationDate 2003-12-01
PublicationDateYYYYMMDD 2003-12-01
PublicationDate_xml – month: 12
  year: 2003
  text: 2003-12-01
  day: 01
PublicationDecade 2000
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Biochemical Society transactions
PublicationTitleAlternate Biochem Soc Trans
PublicationYear 2003
SSID ssj0014146
Score 2.0422018
SecondaryResourceType review_article
Snippet Insulin resistance, when combined with impaired insulin secretion, contributes to the development of type 2 diabetes. Insulin resistance is characterized by a...
SourceID pubmed
SourceType Index Database
StartPage 1152
SubjectTerms Animals
Fatty Acids - physiology
Glucose - metabolism
Insulin - metabolism
Insulin Receptor Substrate Proteins
Insulin Resistance
Osmotic Pressure
Phosphoproteins - chemistry
Phosphoproteins - metabolism
Serine - metabolism
Signal Transduction
Tumor Necrosis Factor-alpha - metabolism
Title Fatty acid-induced insulin resistance: role of insulin receptor substrate 1 serine phosphorylation in the retroregulation of insulin signalling
URI https://www.ncbi.nlm.nih.gov/pubmed/14641015
Volume 31
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Pb9MwFLZaEIILgo0f2wD5gLhEFo3tJfFuW-nGARASQ-I2ObGt7dCkSlOJ7Z_Yv7xnx07SCAQcODSK7NZq_b4-fy_-_B5Cb3MJ_2aVFYQmmSac5ZLkKdMkpaqQcZolXLgitt_SLz-yDwu-mExCNYG-7b9aGtrA1vbk7D9YuxsUGuAebA5XsDpc_8rup7IBXi2LK0Ug3N7Y7f2gN4fI2rJFMLN9DhB0hX2vVbhUdbQGX-Jy1kZxtHanA6PVZbWGV33dKueCOLLWTV3VbTV7TzzDaFYXIl2-761t4ytboKvNUBD0ok1fsbzj959sRSSbxalU5MSeCmm1BB3tBmBvl14-8zv-Sy03P7e032dVeQOL4E3fGJ5xsIFexJ_tms0IUJN06LdZPMDn1yYa-mHgufSXCwT4KLAgTCM4s_GbYO5XSwcLWD44-KrDP_eOknWHrimaAvWy7Hz-udvU4rE_N-Z_TMiWy-n7_gvZLLZ-kFGk4xjP-RP02Icq-LjF2FM00eUO2j0uZVMtr_E77MTDbldmBz04CXcP56GE4C66dWDEQzBiDxDcg_EIWyjiygz6WijiDoo4xi0U8QiK8BkMUMQjKA5H66H4DH0_XZzPPxJfAYQUwGsbwjK7WGsFnsMwzhljqTgUOs84z8VMMGUMV9QkEuJ2oxNdQIAtklgpyqRIjKHP0b2yKvVLhK1L4rqIDVU5V0kus5SBH0piIRUVOt1DL9rJvli1aV4ughn2f9tzgB71aH2F7hvwIfo1mq7V5o0z_R3mq5lr
link.rule.ids 782
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fatty+acid-induced+insulin+resistance%3A+role+of+insulin+receptor+substrate+1+serine+phosphorylation+in+the+retroregulation+of+insulin+signalling&rft.jtitle=Biochemical+Society+transactions&rft.au=Le+Marchand-Brustel%2C+Y&rft.au=Gual%2C+P&rft.au=Gr%C3%A9meaux%2C+T&rft.au=Gonzalez%2C+T&rft.date=2003-12-01&rft.issn=0300-5127&rft.volume=31&rft.issue=Pt+6&rft.spage=1152&rft_id=info:doi/10.1042%2Fbst0311152&rft_id=info%3Apmid%2F14641015&rft_id=info%3Apmid%2F14641015&rft.externalDocID=14641015
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-5127&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-5127&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-5127&client=summon